The ABHD6 Knockout KYSE-30 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for functional genomics studies. They consist of a heterogeneous pool of KYSE-30 cells harboring gene disruptions at the ABHD6 locus, introduced by CRISPR/Cas9-mediated targeting. This polyclonal format captures diverse mutational alleles, providing a robust loss-of-function model without single-cell clonal selection, and is suitable for population-based assays where genetic heterogeneity mimics physiological complexity.
The host cell line, KYSE-30, is a human esophageal squamous epithelial cell line originally established from a well-differentiated esophageal squamous cell carcinoma (ESCC). It is widely used as an in vitro model for studying ESCC pathobiology, including tumor cell proliferation, migration, invasion, and drug responsiveness. The cell line retains key molecular features of esophageal epithelial malignancies, making it a relevant background for investigating gene function in the context of upper gastrointestinal cancers.
ABHD6 encodes an ??/??-hydrolase domain-containing monoacylglycerol lipase that preferentially hydrolyzes the endocannabinoid 2-arachidonoylglycerol (2-AG) to arachidonic acid and glycerol, thereby terminating 2-AG signaling at cannabinoid receptors CB1 and CB2. ABHD6 acts downstream of PPAR?? signaling, with activators such as rosiglitazone modulating its expression. It operates in concert with monoglyceride lipase (MAGL) and fatty acid amide hydrolase (FAAH) to regulate endocannabinoid tone. Loss of ABHD6 elevates 2-AG levels, promoting sustained CB1/CB2 activation and subsequent modulation of MAPK and PI3K/Akt pathways, as well as shifting arachidonic acid flux toward prostaglandin synthesis.
In ESCC, dysregulated lipid metabolism and endocannabinoid signaling are emerging areas of interest in tumor progression and metabolic reprogramming. This ABHD6 knockout polyclonal cell model enables systematic dissection of ABHD6??s role in lipid signaling networks within esophageal cancer cells. Researchers can examine how ABHD6 deficiency influences oncogenic phenotypes, including proliferation, migration, and apoptosis, while also investigating cross-talk between endocannabinoid and arachidonic acid cascades in the tumor microenvironment.
This knockout product is suited for a range of research applications, including mechanistic studies of 2-AG-mediated signaling in ESCC, assessment of ABHD6-dependent regulation of CB1/CB2 receptors, and exploration of PPAR?èCABHD6?C2-AG axis pharmacology. Compatible assays include Western blotting for CB1/CB2 expression, LC-MS/MS quantification of 2-AG and arachidonic acid, cell proliferation (MTT/CCK-8), migration/invasion (Transwell), apoptosis (flow cytometry), RNA-seq, and lipidomics profiling. Rescue experiments employing CB1/CB2 antagonists can further validate pathway engagement. For additional technical specifications, please contact Ascent Research.
